Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: PTCT

PTC Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PTCT. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.54

PTC Therapeutics, Inc. (NASDAQ: PTCT) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 19:55 UTC.

What PTC Therapeutics, Inc. does

This is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders in children and adults. The company markets several approved products including Sephience for phenylketonuria, Translarna and Emflaza for Duchenne muscular dystrophy, Upstaza/Kebilidi for AADC deficiency, and Evrysdi for spinal muscular atrophy, with rights to commercialize additional products in specific regions.

Summarized from PTC Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.54

Revenue, margins & earnings

FY2021: net loss $524M on revenue $539M$539MFY2021FY2022: net loss $559M on revenue $699M$699MFY2022FY2023: net loss $627M on revenue $938M$938MFY2023FY2024: net loss $363M on revenue $807M$807MFY2024FY2025 Net income: $683MFY2025 Taxes & interest: $184MFY2025 Operating costs: $864M$1.73BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-16
  • 2026-10-16DirectorSale-382$23.0K
  • 2026-10-16DirectorSale-2,118$126.1K
  • 2026-10-13EXEC. VP AND CLOOption exercise192$7.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does PTC Therapeutics, Inc. do?

This is a global biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders in children and adults.

When did PTCT last file with the SEC?

PTC Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 19:55 UTC. This page is also available as JSON at /api/data?ticker=PTCT and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PTCT and 5,000+ tickers.

Create a free account — keep PTCT
For your agent
GET /api/data?ticker=PTCT

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt